Research Papers:

Glypican-1 in human glioblastoma: implications in tumorigenesis and chemotherapy

Eduardo Listik and Leny Toma _

Metrics: PDF 419 views  |   Full Text 630 views  |   ?  


Eduardo Listik1 and Leny Toma1

1 Department of Biochemistry, Universidade Federal de São Paulo, São Paulo, SP, Brazil

Correspondence to:

Leny Toma,email: ltoma.bioq@gmail.com

Keywords: glioblastoma; glypican-1; tumorigenesis; chemotherapy resistance; temozolomide

Received: October 23, 2019     Accepted: January 29, 2020     Published: March 03, 2020


Glioblastoma is one of the most common malignant brain tumors, with which patients have a mean survival of 24 months. Glypican-1 has been previously shown to be overexpressed in human glioblastoma and to be negatively correlated with patient’s survival. This study aimed to investigate how glypican-1 influences the tumoral profile of human glioblastoma using in vitro cell line models. By downregulating the expression of glypican-1 in U-251 MG cells, we observed that the cellular growth and proliferation were highly reduced, in which cells were significantly shifted towards G0 as opposed to G1 phases. Cellular migration was severely affected, and glypican-1 majorly impacted the affinity towards laminin-binding of glioblastoma U-251 MG cells. This proteoglycan was highly prevalent in glioblastoma cells, being primarily localized in the cellular membrane and extracellular vesicles, occasionally with glypican-3. Glypican-1 could also be found in cell-cell junctions with syndecan-4 but was not identified in lipid rafts in this study. Glypican-1-silenced cells were much more susceptible to temozolomide than in U-251 MG itself. Therefore, we present evidence not only to support facts that glypican-1 is an elementary macromolecule in glioblastoma tumoral microenvironment but also to introduce this proteoglycan as a promising therapeutic target for this lethal tumor.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27492